Related Experiment Video
Updated: Aug 16, 2026
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
A nitric oxide production bioassay for interferon-gamma
1Department of Surgery and Pharmacology, University of Pittsburgh, School of Medicine, PA 15213, USA.
Insights
A new bioassay detects Interferon-gamma (IFN-gamma) by measuring nitric oxide (NO) produced by macrophages. This sensitive and specific method offers a simple, cost-effective way to monitor IFN-gamma levels for therapeutic applications.
Area of Science:
- Immunology
- Cell Biology
- Biotechnology
Background:
- Interferon-gamma (IFN-gamma) exhibits antitumor and antiviral properties.
- Existing IFN-gamma assays lack simplicity, cost-effectiveness, and specificity.
Purpose of the Study:
- To develop a novel, simple, inexpensive, and specific bioassay for quantifying Interferon-gamma (IFN-gamma).
- To measure IFN-gamma bioactivity by assessing nitric oxide (NO) production in macrophages.
Main Methods:
- Utilized a macrophage cell line (RAW264.7) stimulated with IFN-gamma.
- Quantified nitric oxide (NO) production via nitrite (NO2-) accumulation in culture medium.
- Validated assay sensitivity, specificity, and correlation with ELISA for IFN-gamma protein concentration.
Main Results:
- Developed a linear and logarithmically linear bioassay for IFN-gamma detection (0-10 U/ml and 2-100 U/ml, respectively).
- Achieved high sensitivity with a detection limit of 0.1-0.2 ng/ml IFN-gamma.
- Demonstrated specificity as other cytokines did not induce NO production; assay results correlated well with ELISA.
Conclusions:
- The developed bioassay is a sensitive, specific, and cost-effective method for measuring IFN-gamma bioactivity.
- This novel assay is suitable for monitoring IFN-gamma gene expression and protein accumulation in various research and therapeutic contexts.
- The method provides a valuable tool for advancing IFN-gamma-based therapies.
Abstract:
Interferon-gamma (IFN-gamma), produced by stimulated T lymphocytes and natural killer cells, has an antitumor and antiviral activity by inhibition of cell growth, immunomodulation, and/or activation of macrophages. Although several IFN-gamma assays have been used, there are no simple, inexpensive, and specific assays. We have developed a new bioassay for IFN-gamma which measures the concentration of nitric oxide (NO) generated by a macrophage cell line RAW264.7 stimulated with IFN-gamma. NO production, determined by nitrite (NO2-) accumulation in culture medium, was linear at IFN-gamma concentrations between 0 and 10 U/ml and logarithmically linear between 2 and 100 U/ml, when RAW cells (1 x 10(5) cells/200 microliters/well in 96 well plate) were incubated with murine recombinant IFN-gamma for 24 h. The new assay has a high sensitivity with the detection limit of 0.1-0.2 ng/ml IFN-gamma, which is similar to that of the enzyme-linked immunosorbent assay (ELISA) and antiviral assays. Other cytokines such as IFN-alpha, IFN-beta, tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 beta, IL-2, and IL-6, either alone or in combination did not produce NO from RAW264.7. Exogenous NO2-, NO3- or NO2- plus NO3- did not interfere with the IFN-gamma-induced NO formation as well as NO2- measurement. The IFN-gamma bioactivity, measured by the RAW264.7 bioassay, expressed from the transfected human ovarian tumor cells was closely correlated with the levels of IFN-gamma protein concentration measured by the ELISA. Therefore, our new method can be applicable for monitoring IFN-gamma gene expression and accumulation in culture medium for IFN-gamma therapy.
